Status and phase
Conditions
Treatments
About
The primary objectives of this study are:
Full description
This is a Phase II, randomized, open-label, two-arm, multicenter study of MEDI 522 ± DTIC in previously untreated (other than adjuvant immunotherapy) patients with Stage IV metastatic melanoma (AJCC staging).
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion
Patients must meet all of the following criteria at the time of randomization:
Exclusion
Patients must have none of the following at the time of randomization:
Primary purpose
Allocation
Interventional model
Masking
110 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal